Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
93.88
+0.94 (+1.02%)
Streaming Delayed Price
Updated: 3:22 PM EST, Nov 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
99
100
Next >
2 Healthcare Stocks with Big Upside and 1 to Skip
February 21, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID...
Via
StockStory
Topics
Stocks
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
↗
February 21, 2025
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.
Via
Stocktwits
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
February 20, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
February 20, 2025
From
Glancy Prongay & Murray LLP
Via
Business Wire
Looking Into Merck & Co's Recent Short Interest
↗
February 18, 2025
Via
Benzinga
Beyond The Numbers: 13 Analysts Discuss Merck & Co Stock
↗
February 18, 2025
Via
Benzinga
Merck & Co (MRK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
February 20, 2025
From
Law Offices of Howard G. Smith
Via
Business Wire
Buybacks Galore: 3 Mega-Caps Just Approved Billions in Buybacks
February 20, 2025
Check out these three mega-cap names, valued over $200 billion each, that just authorized a combined $28 billion in buybacks.
Via
MarketBeat
Topics
Earnings
Economy
Intellectual Property
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
↗
February 20, 2025
The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.
Via
Stocktwits
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
February 19, 2025
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Why NYSE:MRK is a Top Pick for Dividend Investors.
↗
February 18, 2025
Why MERCK & CO. INC. (NYSE:MRK) provides a good dividend, while having solid fundamentals.
Via
Chartmill
Decoding Merck & Co's Options Activity: What's the Big Picture?
↗
February 13, 2025
Via
Benzinga
MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors With Large Losses in Merck & Co., Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
February 19, 2025
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports
↗
February 19, 2025
Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors.
Via
Benzinga
Topics
ETFs
Government
World Trade
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
February 19, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Merck & Co. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Filed Against MRK
February 18, 2025
From
Robbins LLP
Via
GlobeNewswire
Europe Approves Merck's Cancer Drug For Two Indications
↗
February 18, 2025
Merck's Welireg receives conditional EU approval for VHL disease-associated tumors and advanced RCC, expanding its global presence across 30+ countries.
Via
Benzinga
This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
↗
February 18, 2025
Via
Benzinga
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
February 18, 2025
Via
Benzinga
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
February 18, 2025
From
Merck & Co., Inc.
Via
Business Wire
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
↗
February 18, 2025
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion.
Via
Benzinga
Topics
Government
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
February 17, 2025
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
MRK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
February 17, 2025
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
February 15, 2025
From
The Schall Law Firm
Via
Business Wire
MarketBeat Week in Review – 02/10 - 02/14
February 15, 2025
Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in
Via
MarketBeat
Topics
Credit Cards
Economy
Government
10 Health Care Stocks With Whale Alerts In Today's Session
↗
February 14, 2025
Via
Benzinga
In a market where value is scarce, NYSE:MRK offers a refreshing opportunity with its solid fundamentals.
↗
February 14, 2025
MERCK & CO. INC. has caught the attention as a great value stock. NYSE:MRK excels in profitability, solvency, and liquidity, all while being very reasonably priced.
Via
Chartmill
MRK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
February 14, 2025
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Rosen Law Firm Urges Merck & Co., Inc. (NYSE: MRK) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
February 13, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump's Secretary Of Health: Health Care Stocks To Watch
↗
February 13, 2025
The U.S. Senate voted on Thursday to confirm President Donald Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
Via
Benzinga
Topics
Government
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today